The drug, combined with Celgene's Vidaza, Otsuka's Dacogen or low-dose cytarabine, showed strong response rates in elderly and unfit AML patients, historically a hard-to-treat population.
The data for AMG 420 are early, an Amgen executive said, but where to place the drug relative to CAR-Ts is a "million-dollar question."
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
The company's adoptive cell therapy produced responses in central nervous system PTLD, a frequently lethal complication of stem cell and solid organ transplants.
The company presented Phase I data from its study of allogeneic CAR-T UCART19, as well as preclinical data on a BCMA CAR-T for multiple myeloma.
A company analysis deemed the patient's myelodysplastic syndrome was unrelated to LentiGlobin, but a news report indicated it may have stemmed from the conditioning regimen used in the trial.
Bispecific antibodies like Amgen's AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies - which target the same antigen - be possible?
Join us on February 26 at 3 pm ET, and we’ll dive into the key areas where practices are losing time and money and provide solutions to overcome them.
After its shares plunged nearly 50 percent in October, Alnylam, the double-stranded RNAi company, is trying to resurrect itself with new data at the annual meeting of the American Society of Hematology (ASH).